Dr Angela Pine

Biography

Research Interests: My research focuses on the early detection, prevention and management of Human Papillomavirus (HPV) infections and associated diseases. My group investigates factors associated with persistent infection and develops novel treatment modalities. We work closely with other universities, industry and key stakeholders to develop diagnostic solutions and improve access to cervical screening whilst reducing health inequalities globally. Investigating the impact of health-literacy on HPV vaccination uptake and cervical screening guidance adherence. Specialising in functional nucleic acids (DNAzymes, RNA-cleaving DNAzymes), nucleic acid based nanoparticles, molecular biology, and cancer research. Skilled in predictive modelling of nucleic acid interactions, computational modelling and machine learning using R as well as having 'wet-lab' expertise. I have a passion for biologically inspired engineering, designing and developing new ways to use biological design in innovations that answer unmet scientific need. Trained as an HCPC registered Biomedical Scientist. Fellow of the Institute of Biomedical Science. Member of the IBMS Cellular Pathology Specialist Advisory Panel. Masters by dissertation in Cell & Molecular Biology. Scholarship PhD in Cell & Molecular Biology, developing a novel gene therapy and nanoparticle delivery system for castrate resistant prostate cancer (end-stage) resulting in 2 patents (Pine et al., 2023). Founder of 10zyme, a company that aims to make cervical screening accessible to all. Member of the HPV Coalition delivering a roadmap to the UK governments on the elimination of HPV-related cancers.

Qualifications

• PhD Cell & Molecular Biology University of Essex, (2021)

• MSc by dissertation Cell & Molecular Biology University of Essex, (2016)

• BSc Biomedical Science University of Essex, (2014)

Appointments

University of Essex

• Lecturer, School of Life Sciences, University of Essex (1/10/2022 - present)